Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 16/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | NNMT | P40261 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28604915 | 1.00 | MAP4K1 (0.55) | MAP4K1CYP3A4NNMTGSK3B | |
| SCHEMBL21920575 | 1.00 | MAP4K1 (0.55) | MAP4K1CYP3A4NNMTGSK3B | |
| SCHEMBL21920324 | 0.93 | MAP4K1 (0.48) | MAP4K1CYP3A4NNMTGSK3B | |
| SCHEMBL30087806 | 0.93 | MAP4K1 (0.48) | MAP4K1CYP3A4NNMTGSK3B | |
| SCHEMBL21920327 | 0.93 | MAP4K1 (0.48) | MAP4K1CYP3A4NNMTGSK3B | |
| SCHEMBL30087805 | 0.93 | MAP4K1 (0.48) | MAP4K1CYP3A4NNMTGSK3B | |
| SCHEMBL21919863 | 0.89 | MAP4K1 (0.45) | MAP4K1CYP3A4 | |
| SCHEMBL30087946 | 0.89 | MAP4K1 (0.45) | MAP4K1CYP3A4 | |
| SCHEMBL28614186 | 0.89 | MAP4K1 (0.45) | MAP4K1CYP3A4 | |
| Hydrochloric Acid SCHEMBL30088084 | 0.88 | MAP4K1 (0.44) | MAP4K1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | GENENTECH, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12208088-B2 | Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof | HIPK1, NEK1, HIPK2 | MAP4K1 36/4885CYP3A4 3696/4885NNMT 1766/4885 |
| US-20220370420-A1 | SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF | HIPK1, NEK1, HIPK2 | MAP4K1 36/4885CYP3A4 3696/4885NNMT 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.